- Age 18 years or older
- IV nicardipine can be initiated within 4.5 hours of symptom onset.
- Clinical signs consistent with the diagnosis of stroke, including impairment of
language, motor function, cognition, and/or gaze, vision, or neglect.
- Total Glasgow Coma Scale (GCS) score (aggregate of verbal, eye, and motor response
scores) of 5 or greater at time of emergency department (ED) arrival.
- International normalized ratio (INR) value < 1.5
- CT scan demonstrates intraparenchymal hematoma with manual hematoma volume measurement
- For subjects randomized prior to IV antihypertensive administration: SBP greater than
180 mmHg* prior to IV antihypertensive treatment (this includes pre-hospital
treatment) AND WITHOUT spontaneous SBP reduction to below 180 mmHg at the time of
- For subjects randomized after IV antihypertensive administration: SBP greater than 180
mmHg* prior to IV antihypertensive treatment (this includes pre-hospital treatment)
AND WITHOUT SBP reduction to below 140 mmHg at the time of randomization.
- Informed consent obtained by subject, legally authorized representative, or next of
- Notes: The unit "mmHg" stands for "millimeters of mercury", a standard way of
measuring blood pressure. Patients with SBP < 180 mmHg should be monitored for
4.5 hours from symptom onset as their SBP may rise to eligible levels before the
eligibility window closes.
- ICH is due to previously known neoplasms, arteriovenous malformation (AVM), or
- Intracerebral hematoma considered to be related to trauma.
- ICH located in infratentorial regions such as pons or cerebellum.
- Intraventricular hemorrhage (IVH) associated with intraparenchymal hemorrhage and
blood completely fills one lateral ventricle or more than half of both ventricles.
- Patient to receive immediate surgical evacuation.
- Current pregnancy, or parturition within previous 30 days, or active lactation.
- Use of dabigatran within the last 48 hours**.
- A platelet count less than 50,000 per microliter (µL or mm3)
- Known sensitivity to nicardipine.
- Pre-morbid disability requiring assistance in ambulation or activities of daily
- Subject's living will precludes aggressive ICU management.
- Subject is currently participating in another interventional clinical trial
- Use of dabigatran was clarified through investigator presentations, educational
materials, and clinical tools to include newer similar class medications (such as
rivaroxaban, apixaban, and edoxaban) that were being developed and in various
stages of approval across enrolling countries through the course of this trial,
in the event that patients using these medications may have been encountered
Eligibility CriteriaPhysical gender of individuals who may participate in the protocol.
Minimum and/or maximum age of participants.
Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study.